Latest Breaking News On - Five prime - Page 11 : comparemela.com
Amgen s Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
П ять прем єр за п ять місяців: у київському цирку розповіли, що показали цього сезону
ukrinform.ua - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ukrinform.ua Daily Mail and Mail on Sunday newspapers.
socaltech.com
Thousand Oaks-based
Amgen said this morning that it has successfully completed its $1.9 billion acquisition of
Five Prime Therapeutics, a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. Amgen paid $38.00 per share in cash for Five Prime Therapeutics. Five Prime s programs include bemarituzumab, a Phase 3 trial-ready, first-in-class program for gastric cancer.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
April 16, 2021 GMT
Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)
THOUSAND OAKS, Calif., April 16, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash. The aggregate consideration to be paid by Amgen to complete the tender offer and the subsequent merger is approximately $1.9 billion without giving effect to related transaction fees and expenses.
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.